Panchakarma in autoimmune pancreatitis: A single-case study
| Autor: | Panchakshari D Patil, Anup B Thakar, Rajkala P Patil |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Madhutailika Basti Levothyroxine Case Report General Medicine Anticholinergic agents Enema Virechana medicine.disease Gastroenterology medicine.anatomical_structure Panchakarma Internal medicine Duodenum Medicine Pancreatitis Grahani Dosha business Body mass index Autoimmune pancreatitis medicine.drug |
| Zdroj: | Ayu |
| ISSN: | 0974-8520 |
| DOI: | 10.4103/ayu.ayu_15_20 |
| Popis: | Autoimmune pancreatitis (AIP) is the pancreatic manifestation of a systemic fibro-inflammatory disorder. AIP is a unique form of pancreatitis in which autoimmune mechanisms are suspected to be involved in the pathogenesis. AIP is a rare disorder, its exact cause is unknown, but it is thought to be caused by the body’s immune system attacking the pancreas and it responds to steroid therapy only. In Ayurveda, although there is no synonym for AIP, but has a resemblance in clinical features of Grahani Dosha (derangement of duodenum and intestine). The cause of Grahani Dosha is Mandagni (hypofunctioning of Agni) and Panchakarma therapy increases Agni. As per Charaka Samhita, treatment for Grahani Dosha amongst the Panchakarma therapy is Virechana (therapeutic purgation) and Basti (medicated enema). The present case report is of a 30-year-old female, diagnosed as case of AIP with multisystem involvement with increased level of immunoglobulin G (IgG), glycosylated heamoglobin (HbA1c), cholesterol, triglycerides, low-density lipoprotein (LDL) and body mass index (BMI). The patient was on anticholinergic agents, antacids, levothyroxine, multivitamin along with iron and antihistamine drugs since 1 year, but with not much relief. Patient was treated with classical Virechana and Madhutailika Basti. It was observed after the completion of therapy, that there was decrease in IgG, HbA1c, S. cholesterol, S. triglyceride, low density lipoprotein (LDL) and body mass index (BMI). This shows that Virechana and Basti play a significant role in patient with AIP associated with other disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|